Home

Multiplicom and IFFMEDIC sign agency agreement for Central Europe, leveraging access to our molecular genetic tests

    Today Multiplicom and IFFMEDIC announced that IFFMEDIC will act as Multiplicom's agent for the marketing and sales of its molecular diagnostic kits in Central Europe. This agreement is in line with Multiplicom’s strategy to improve access to innovative molecular genetic tests as well as providing expert technical support to medical genetics labs.
    Multiplicom is a Belgian diagnostics company, specialized in the design, development, production, and commercialization of innovative molecular genetic tests based on next generation sequencing. IFFMEDIC is a Germany-based company focusing on marketing and sales of diagnostics. Both companies today signed an agreement under which they will work closely together to promote Multiplicom's products, to close sales agreements, and to provide expert support to customers throughout Germany, Austria, and Eastern Europe. Whereas Multiplicom was already selling products to key opinion leaders in Germany, the parties underline the strategic importance of this partnership for the further development of these diagnostic markets by regular visits to the growing list of prospects and customers.
    Dirk Pollet, CEO of Multiplicom states, “This agreement with IFFMEDIC is key in our marketing and sales strategy. Germany is a major market where massive parallel sequencing based molecular diagnostics is entering clinical routine. We are delighted to team up with IFFMEDIC since they are close to the key opinion leaders, the market, and major customers in these regions.” Luc Segers, VP Marketing and Sales for Multiplicom adds, “Both teams will work closely together in the market place to sign up customers and provide expert technical support."
    Andreas Iffland, General Manager IFFMEDIC notes, "The market entry of the next generation of genetic cancer tests and our intensive marketing and product development collaboration with Multiplicom will be the key strategy for our sales, customer service, and marketing teams across Central Europe."
    The press release can be found here

In the spotlight:

1. BRCA MASTR Assay upgrade to v2.1.

The BRCA MASTR Assay v2.0 was introduced in the first trimester of 2011. Since then numerous users have been working with the assay and provided us with very supportive feedback. Based on this information we have improved the assay and are consequently upgrading to version 2.1. more...

2. Multiplicom is expanding its commercial capabilities and is recruiting a Sales Representative Molecular Diagnostics.

You can find the job description and expected profile here